Phase 2 Study to Evaluate Efficacy and Safety of MR13A9 in Hemodialysis Patients with Uremic Pruritus.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors Maruishi Pharmaceutical
- 01 Nov 2017 Status changed from active, no longer recruiting to completed.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Mar 2017 Planned End Date changed from 30 Apr 2017 to 31 Oct 2017.